Immunovantinc Stock Analysis
| IMVT Stock | USD 28.32 0.11 0.39% |
ImmunovantInc is undervalued with Real Value of 35.09 and Target Price of 43.85. The main objective of ImmunovantInc stock analysis is to determine its intrinsic value, which is an estimate of what ImmunovantInc is worth, separate from its market price. There are two main types of ImmunovantInc's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect ImmunovantInc's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of ImmunovantInc's stock to identify patterns and trends that may indicate its future price movements.
The ImmunovantInc stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. ImmunovantInc is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. ImmunovantInc Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and ImmunovantInc's ongoing operational relationships across important fundamental and technical indicators.
ImmunovantInc |
ImmunovantInc Stock Analysis Notes
About 56.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.81. ImmunovantInc had not issued any dividends in recent years. Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people. To learn more about ImmunovantInc call Andy Deig at (917) 580-3099 or check out https://immunovant.com.ImmunovantInc Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. ImmunovantInc's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding ImmunovantInc or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| ImmunovantInc generated a negative expected return over the last 90 days | |
| ImmunovantInc has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (210.96 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ImmunovantInc currently holds about 427.2 M in cash with (188.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.66. | |
| ImmunovantInc has a very weak financial position based on the latest SEC disclosures | |
| Roughly 56.0% of the company shares are held by company insiders | |
| Latest headline from zacks.com: What Makes Immunovant a New Buy Stock |
ImmunovantInc Upcoming and Recent Events
Earnings reports are used by ImmunovantInc to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ImmunovantInc previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 2nd of February 2024 Upcoming Quarterly Report | View | |
| 27th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of May 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
ImmunovantInc Largest EPS Surprises
Earnings surprises can significantly impact ImmunovantInc's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-02-14 | 2019-12-31 | -0.25 | -0.28 | -0.03 | 12 | ||
2021-06-01 | 2021-03-31 | -0.33 | -0.29 | 0.04 | 12 | ||
2022-08-05 | 2022-06-30 | -0.4 | -0.35 | 0.05 | 12 |
ImmunovantInc Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ImmunovantInc is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ImmunovantInc backward and forwards among themselves. ImmunovantInc's institutional investor refers to the entity that pools money to purchase ImmunovantInc's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Nuveen Asset Management, Llc | 2023-12-31 | 1.2 M | Logos Global Management Lp | 2023-12-31 | 1.2 M | Cormorant Asset Management, Llc | 2023-12-31 | 1.2 M | Redmile Group, Llc | 2023-09-30 | 1.1 M | Deep Track Capital, Lp | 2023-12-31 | 1000 K | Commodore Capital Lp | 2023-12-31 | 1000 K | Boxer Capital Llc | 2023-12-31 | 1000 K | Rock Springs Capital Management Lp | 2023-12-31 | 983.3 K | Capital Research Global Investors | 2023-12-31 | 976.2 K | Fmr Inc | 2023-12-31 | 7.9 M | Vanguard Group Inc | 2023-12-31 | 5.8 M |
ImmunovantInc Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.13 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate ImmunovantInc's market, we take the total number of its shares issued and multiply it by ImmunovantInc's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.ImmunovantInc Profitablity
ImmunovantInc's profitability indicators refer to fundamental financial ratios that showcase ImmunovantInc's ability to generate income relative to its revenue or operating costs. If, let's say, ImmunovantInc is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, ImmunovantInc's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of ImmunovantInc's profitability requires more research than a typical breakdown of ImmunovantInc's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.07) | (0.07) | |
| Return On Capital Employed | (1.16) | (1.10) | |
| Return On Assets | (0.07) | (0.07) | |
| Return On Equity | (1.16) | (1.11) |
Management Efficiency
ImmunovantInc has return on total asset (ROA) of (0.2715) % which means that it has lost $0.2715 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4451) %, meaning that it created substantial loss on money invested by shareholders. ImmunovantInc's management efficiency ratios could be used to measure how well ImmunovantInc manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.07 in 2024. Return On Capital Employed is likely to gain to -1.1 in 2024. Total Current Liabilities is likely to gain to about 52.3 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 317.6 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.11 | 1.05 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 1.11 | 1.05 | |
| Enterprise Value Over EBITDA | (6.88) | (7.23) | |
| Price Book Value Ratio | 8.98 | 5.79 | |
| Enterprise Value Multiple | (6.88) | (7.23) | |
| Price Fair Value | 8.98 | 5.79 | |
| Enterprise Value | 195.6 K | 185.8 K |
The analysis of ImmunovantInc's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze ImmunovantInc's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of ImmunovantInc Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.697 |
Technical Drivers
As of the 19th of April, ImmunovantInc retains the Risk Adjusted Performance of (0.14), market risk adjusted performance of (0.67), and Standard Deviation of 2.43. ImmunovantInc technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to interpolate and analyze data for thirteen technical drivers for ImmunovantInc, which can be compared to its competitors. Please check out ImmunovantInc variance and skewness to decide if ImmunovantInc is priced fairly, providing market reflects its last-minute price of 28.32 per share. Given that ImmunovantInc has information ratio of (0.27), we strongly advise you to confirm ImmunovantInc's regular market performance to make sure the company can sustain itself at a future point.ImmunovantInc Price Movement Analysis
The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. ImmunovantInc middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for ImmunovantInc. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
ImmunovantInc Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ImmunovantInc insiders, such as employees or executives, is commonly permitted as long as it does not rely on ImmunovantInc's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ImmunovantInc insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ImmunovantInc Predictive Daily Indicators
ImmunovantInc intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ImmunovantInc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
ImmunovantInc Corporate Filings
| 15th of April 2024 Other Reports | ViewVerify | |
F4 | 10th of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 4th of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 23rd of February 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of February 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 12th of February 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 9th of February 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 29th of January 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
ImmunovantInc Forecast Models
ImmunovantInc's time-series forecasting models are one of many ImmunovantInc's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ImmunovantInc's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About ImmunovantInc Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how ImmunovantInc prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ImmunovantInc shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as ImmunovantInc. By using and applying ImmunovantInc Stock analysis, traders can create a robust methodology for identifying ImmunovantInc entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | 0.00 | 0.00 | |
| Operating Profit Margin | 0.00 | 0.00 | |
| Net Profit Margin | 0.00 | 0.00 | |
| Gross Profit Margin | 0.00 | 0.00 |
Current ImmunovantInc Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ImmunovantInc analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ImmunovantInc analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 43.85 | Strong Buy | 17 | Odds |
Most ImmunovantInc analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand ImmunovantInc stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of ImmunovantInc, talking to its executives and customers, or listening to ImmunovantInc conference calls.
ImmunovantInc Stock Analysis Indicators
ImmunovantInc stock analysis indicators help investors evaluate how ImmunovantInc stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading ImmunovantInc shares will generate the highest return on investment. By understating and applying ImmunovantInc stock analysis, traders can identify ImmunovantInc position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 493.8 M | |
| Common Stock Shares Outstanding | 123.1 M | |
| Total Stockholder Equity | 362.5 M | |
| Total Cashflows From Investing Activities | -197 K | |
| Tax Provision | 9000.00 | |
| Property Plant And Equipment Net | 1.5 M | |
| Cash And Short Term Investments | 376.5 M | |
| Cash | 376.5 M | |
| Accounts Payable | 1.4 M | |
| Net Debt | -375.3 M | |
| 50 Day M A | 33.3308 | |
| Total Current Liabilities | 43.3 M | |
| Other Operating Expenses | 208.3 M | |
| Non Current Assets Total | 1.5 M | |
| Common Stock Total Equity | 13 K | |
| Stock Based Compensation | 32.3 M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmunovantInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For more information on how to buy ImmunovantInc Stock please use our How to Invest in ImmunovantInc guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for ImmunovantInc Stock analysis
When running ImmunovantInc's price analysis, check to measure ImmunovantInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmunovantInc is operating at the current time. Most of ImmunovantInc's value examination focuses on studying past and present price action to predict the probability of ImmunovantInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmunovantInc's price. Additionally, you may evaluate how the addition of ImmunovantInc to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is ImmunovantInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmunovantInc. If investors know ImmunovantInc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmunovantInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.81) | Return On Assets (0.27) | Return On Equity (0.45) |
The market value of ImmunovantInc is measured differently than its book value, which is the value of ImmunovantInc that is recorded on the company's balance sheet. Investors also form their own opinion of ImmunovantInc's value that differs from its market value or its book value, called intrinsic value, which is ImmunovantInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmunovantInc's market value can be influenced by many factors that don't directly affect ImmunovantInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmunovantInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmunovantInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmunovantInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.